Discussions

Exosomal peptidomic detection is a critical process that determines the efficacy and specificity of the therapeutic agent. ADCs represent a novel class of cancer therapeutics that combine the targeting capabilities of antibodies with the cytotoxic potency of drugs. The screening process involves identifying specific tumor-associated antigens that are abundantly expressed on cancer cells but minimally present on normal cells. This ensures that the ADC can effectively distinguish between healthy and malignant cells, thereby increasing therapeutic efficacy while minimizing off-target effects. Advanced technologies in molecular biology and bioinformatics are utilized to streamline the screening process, enabling researchers to identify the most promising targets for ADC development, ultimately improving treatment outcomes for cancer patients.